MetLife Investment Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

MetLife Investment Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,854	Closed	-$501K	–	2592
2021 Q3	$501K	Hold	24,854	–	–	﹤0.01%	1519
2021 Q2	$928K	Sell	24,854 -4,181	-14%	-$128K	0.01%	1211
2021 Q1	$742K	Hold	29,035	–	–	0.01%	1294
2020 Q4	$640K	Hold	29,035	–	–	0.01%	1358
2020 Q3	$522K	Hold	29,035	–	–	0.01%	1346
2020 Q2	$737K	Buy	29,035 +6,181	+27%	+$133K	0.01%	1169
2020 Q1	$420K	Hold	22,854	–	–	0.01%	1309
2019 Q4	$503K	Sell	22,854 -4,933	-18%	-$99.3K	0.01%	1458
2019 Q3	$399K	Hold	27,787	–	–	﹤0.01%	1548
2019 Q2	$438K	Buy	27,787 +6,076	+28%	+$82.6K	﹤0.01%	1561
2019 Q1	$318K	Hold	21,711	–	–	﹤0.01%	1720
2018 Q4	$232K	Hold	21,711	–	–	﹤0.01%	1821
2018 Q3	$331K	Hold	21,711	–	–	﹤0.01%	1794
2018 Q2	$266K	Buy	+21,711	New	+$273K	﹤0.01%	1778

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

MetLife Investment Management's DRNA Position: Q4 2021 in Review

MetLife Investment Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 24,854 shares — an estimated $501K sold.

MetLife Investment Management first reported a position in DRNA in Q2 2018 and held it in 14 quarters. The position peaked at $928K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

MetLife Investment Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
MetLife Investment Management sold 24,854 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $501K.
MetLife Investment Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2018 and held it in 14 quarters.
MetLife Investment Management's Dicerna Pharmaceuticals, Inc. position peaked at $928K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.